Abstract
Background: Dihydroceramide desaturase 1 (DES) is the enzyme responsible for converting dihydroceramide into ceramide in the de novo sphingolipid biosynthesis pathway. Dihydroceramide can inhibit ceramide channel formation to interfere with apoptosis. We have shown that following ceramide synthase knockdown, photodynamic therapy (PDT), a cancer treatment modality, is associated with decreased levels of ceramides and dihydroceramides in cells that are resistant to apoptosis. Aim: Here we investigated the effect of DES knockdown on the sphingolipid profile and apoptosis in human head and neck squamous carcinoma cells after PDT with the silicon phthalocyanine Pc 4. Materials and Methods: Following siRNA transfection and PDT treatment, quantitative real-time polymerase chain reaction for quantification of DES mRNA, immunoblotting for protein expression, mass spectrometry for sphingolipid analysis, spectrofluorometry for caspase 3-like (DEVDase) activity, flow cytometry for apoptosis detection, and trypan blue assay for cell viability evaluation, were performed. Results: Down-regulation of DES led to a substantial increase in levels of dihydroceramides without affecting ceramide levels. PDT-induced accumulation of individual dihydroceramides and global ceramides was increased by DES knockdown. Concomitantly, mitochondrial depolarization, DEVDase activation, late-apoptosis and cell death were attenuated by DES knockdown. Early apoptosis, however, was enhanced. Conclusion: Our findings support the following: (i) dihydroceramide reduces pro-apoptotic effects of ceramide; (ii) cells adapt to DES knockdown to become more sensitive to ceramide and early-apoptosis; (iii) DES is a potential molecular target for regulating apoptotic resistance to PDT.
The sphingolipid ceramide can be generated via the de novo sphingolipid biosynthesis pathway (Figure 1), in which dihydroceramide desaturase 1 (DES) introduces the 4,5-trans double bond into the sphingoid backbone of dihydroceramide to give rise to ceramide. The de novo ceramide production is activated by apoptotic inducers (1). Although originally thought to be inert, dihydroceramide has been implicated in various processes, including autophagy, cell-cycle arrest and apoptosis (2, 3). Dihydroceramide can inhibit ceramide channel formation and has been proposed to have a negative impact on apoptosis (4). DES knockdown-associated accumulation of dihydroceramide results in cell-cycle arrest (5). Fenretinide, an oxidative stress inducer and a chemopreventive agent, is an in vitro inhibitor of DES that induces intracellular accumulation of dihydroceramide and apoptosis (5, 6).
We have shown that the de novo sphingolipid biosynthesis pathway affects apoptosis after photodynamic therapy (PDT), a cancer treatment modality (7-9). PDT utilizes a light-absorbing photosensitizer, visible light and oxygen to generate reactive oxygen species that can destroy malignant cellular targets by apoptosis (10, 11). Recently we demonstrated that the knockdown of ceramide synthase 1, or 6, is associated with reduction in ceramides and dihydroceramides, resulting in apoptotic resistance to PDT (12, 13). The objective of the present study was to test for the role of DES in PDT-induced sphingolipid production and apoptosis directly. To this end, DES was down-regulated in UM-SCC-22A, a human head and neck squamous carcinoma cell line.
Materials and Methods
Materials. The silicon phthalocyanine Pc 4, HOSiPcOSi(CH3)2 (CH2)3N(CH3)2, was kindly supplied by Dr. Malcolm E. Kenney (Case Western Reserve University, Cleveland, OH, USA). Dulbecco's modified Eagle's medium (DMEM) and serum were from Invitrogen Life Sciences (Grand Island, NY, USA) and Hyclone (Logan, UT, USA), respectively. UM-SCC-22A, a human head and neck squamous carcinoma cell line from hypopharynx (14, 15), was kindly supplied by Dr. Thomas Carey (University of Michigan, Ann Arbor, MI, USA).
Cell culture. UM-SCC-22A cells were grown in DMEM containing 10% fetal bovine serum, 1% non-essential amino acids, 100 U/ml penicillin, and 100 μg/ml streptomycin. Cells were maintained at 37°C in an incubator with a 5% CO2 atmosphere, and were treated in the growth medium.
siRNA transfection and PDT treatment. The siRNA targeting the sequence CCU UCA AUG UGG GUU AUC ATT of human DES was from Invitrogen Life Sciences. For control siRNA, AllStars Negative Control siRNA from Qiagen (Valencia, CA, USA) was used. UM-SCC-22A cells were transfected with double-strand siRNAs using Oligofectamine from Invitrogen Life Sciences, according to the manufacturer's instructions. To optimize the concentration of DES, preliminary dose-response experiments (10-40 nM DES) were carried out. As described previously (12), cells (1×105 cells/ml) were transfected with 25 nM of each siRNA. Twenty-four hours after transfection, cells were collected and seeded in fresh-growth medium. Following overnight exposure to Pc 4 (250 and 500 nM), cells were irradiated with red light (2 mW/cm2; λmax ~670 nm) using a light-emitting diode array (EFOS; Mississauga, ONT, Canada) at a fluence of 200 mJ/cm2 at room temperature. Following PDT, cells were incubated at 37°C for 2 or 24 h, collected on ice and processed for various analyses. For mass spectrometric analysis, cells were washed twice with cold phosphate-buffered saline, sonicated in a mixture of ethyl acetate/methanol (1:1, v/v), dried under nitrogen, and shipped overnight on dry ice to the Lipidomics Shared Resource (Medical University of South Carolina, Charleston, SC, USA) for further processing.
Sphingolipid analysis by quantitative high-performance liquid chromatography (HPLC)/mass spectrometry (MS). Following extraction, sphingolipids were separated by HPLC, introduced to an electrospray ionization source and then analyzed by double-MS using a TSQ Quantum Access mass spectrometer from Thermo-Fisher Scientific (Waltham, MA, USA), as described previously (16).
RNA extraction and quantitative real-time polymerase chain reaction (PCR). Total RNA isolation was performed with the RNeasy® Mini Kit (Qiagen) according to the manufacturer's instructions. cDNA was synthesized from 1 μg of the total RNA using iScript™ cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). The concentration and quality of total RNA preparations were evaluated spectrophotometrically. PCR was performed on a Bio-Rad iCycler detection system using Bio-Rad SsoFast Probes Supermix™ and TaqMan® Gene Expression Assays (Life Technologies Corporation, Carlsbad, CA, USA) primer/probe sets for DES and the ribosomal protein L13A (RPL13A). Initial steps of PCR were 30 s at 85°C, followed by 40 cycles consisting of a 5 s at 95°C, followed by 10 s at 60°C. Determination of the relative quantities of DES mRNA against the internal control housekeeping gene rpl13a, was performed by following a ΔCT method (17).
Immunoblotting. Following PDT, cells were collected, lysed in reducing Laemmli buffer, boiled and then subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and western immunoblotting, as reported previously (7, 18). Equal protein loading was confirmed using antibody against heat shock protein 90 (HSP-90). Antibody against DES (MLD 3906) was synthesized by Dr. Gordon N. Gill (University of California, San Diego, CA, USA). Mouse monoclonal anti-HSP-90 was from BD Biosciences (San Diego, CA, USA). Following visualization of blots using the ECL Plus chemifluorescence kit and STORM 860 imaging system (GE Healthcare, Piscataway, NJ, USA), they were quantified by ImageQuant 5.2 (GE Healthcare).
Caspase 3-like (DEVDase) activity assay. As described previously (12), following PDT, cell harvesting and cell lysis, DEVDase activity was measured using a fluorogenic derivative of the tetrapeptide substrate Asp-Glu-Val-Asp [Ac-DEVD-AMC (7-amino-4-methylcoumarin)] from Enzo Life Sciences (Farmingdale, NY, USA), and an F-2500 spectrofluorometer (Hitachi; Dallas, TX, USA) (380 nm excitation, 460 nm emission).
Mitochondrial membrane depolarization measurement. The lipophilic cationic dye JC-1 (5,5’,6,6’-tetrachloro-1,1’3,3’-tetraethylbenzimidazolylcarbocyanine iodide) from BD Biosciences (San Diego, CA, USA) was used to determine mitochondrial membrane potential by flow cytometry, as we have described previously (8, 12, 19). Following PDT, cells were harvested and processed for flow cytometry according to the manufacturer's instructions (BD Biosciences). A BD LSR II flow cytometer was used for analysis (BD Biosciences).
Trypan blue dye exclusion assay. After PDT, cells were harvested, re-suspended in cell growth medium and diluted 1:1 with 0.4% trypan blue stain from Sigma-Aldrich (St. Louis, MO, USA). Stained and unstained cells were counted using a hemocytometer. Trypan blue-positive cells were designated as dead cells.
Statistical analysis. For MS data, a linear model was used to determine the effects of cell line and PDT (independent variables) on the concentration of sphingolipids (dependent variable). The nominal p-values obtained from the model were adjusted across all individual sphingolipids to control the false-discovery rate at 5%. For effects on global ceramides and dihydroceramides, a one-sample t-test was used on individual log2 ratios (PDT/control) within the family of ceramides or dihydroceramides, in order to determine whether the ratios were different from unity. All analyses were performed using an R statistical language. For all other data the average value and the standard error were calculated for at least n=3. Data were analyzed for statistically significant differences (p≤0.05) between groups using a t-test of unequal variance.
Results
DES was down-regulated at-rest and after PDT. To verify down-regulation of DES in siDES-transfected cells (siDES cells), DES mRNA and protein expression were determined. DES mRNA was reduced by >90% 48 h after transfection (Figure 2A) and the effect was maintained after 72 h (not shown). DES protein levels were reduced by 48% after DES knockdown (Figure 2B; quantifiable data not shown).
We next examined the effect of PDT on DES expression in both cell types. As shown in Figure 2C, DES was degraded after treatment with 500 nM Pc 4/PDT in siControl-transfected cells (siControl cells). The effect was not apparent at 250 nM Pc 4/PDT. In untreated siDES cells, DES was down-regulated. No further effect of PDT on the protein expression was detected.
Resting levels of global dihydroceramides were substantially raised by DES knockdown. At rest, DES silencing markedly increased global levels of dihydroceramides without affecting the levels of ceramides (Table I). Individually, the resting levels of C14-, C16-, C22-, C22:1-, C24-, C24:1-, C26-, and C26:1-dihydroceramide were significantly increased by DES knockdown (Table II). The resting levels of individual ceramides were not significantly affected by DES knockdown (not shown). The accumulation of dihydrosphingosine, an intermediate in the de novo biosynthesis pathway was significantly increased after the knockdown (data not shown). Overall, increases in global and individual dihydroceramides further verifies DES knockdown.
The effect of DES knockdown on the sphingolipid profile after PDT. We then explored the effect of DES silencing on the sphingolipid profile in siControl and siDES cells at 2 h post-PDT (Table III). Globally, ceramides were increased in siControl cells after both PDT doses. In siDES cells, a significant increase in global ceramides was observed only after the higher PDT dose, and that increase was higher than in siControl cells (p<0.011). Global levels of dihydroceramides were increased in both cell types after both PDT doses. The responses were generally lower in siDES cells than in siControl cells due to higher baseline levels of dihydroceramides. Thus, DES knockdown is associated with increases in global dihydroceramides and, at the higher PDT dose, global ceramide levels.
Among individual ceramides that were significantly increased after PDT in both cell types are: C14-, C16-, C18-, and C18:1-ceramide (Table IV). There were no differences between the two cell types in individual ceramide responses to PDT. Individual dihydroceramides that were significantly increased post-PDT in both cell types are: C14-, C16-, C18-, C18:1-, C20:1-, and C22:1-dihydroceramide (Table V). PDT-induced levels of C14-, C16-, C18-, C22:1-, and C24:1-dihydroceramide were significantly higher (p<0.05) in siControl than in siDES cells. In contrast, the induced accumulation of C20- and C24-dihydroceramide was higher (p<0.03) in siDES-cells than in their control counterparts. In addition, significant increases in dihydrosphingosine and sphingosine were observed after PDT in both cell types (Table VI). Dihydrosphingosine response was greater in siControl cells than in siDES cells.
DES knockdown inhibited PDT-induced DEVDase activation. To assess the requirement for DES in PDT-induced caspase-3 activation, we measured the DEVDase activity at 2 h after PDT in both cell types. We found that DES knockdown led to a 23 and 34% reduction in DEVDase activation, after corresponding PDT doses (Figure 3). These findings are consistent with the idea that DES is involved in PDT-induced activation of DEVDase.
DES knockdown suppressed mitochondrial depolarization after PDT. The loss of mitochondrial membrane potential accompanies PDT-evoked apoptosis (8, 21). We asked whether DES affects apoptosis at the mitochondrial level 24 h after PDT. As shown in Figure 4A, following DES knockdown, mitochondrial depolarization was reduced by 18%, after 250 nM Pc 4/PDT. A similar effect was observed after 500 nM Pc 4/PDT. The data support the notion that mitochondrial depolarization after PDT is DES-dependent.
The effect of DES knockdown on PDT-induced apoptosis. We investigated the role of DES in apoptosis at 24 h after PDT using annexin V and propidium iodide as early- and late-apoptotic markers, respectively. As depicted in Figure 4B, following DES knockdown the appearance of annexin V+/propidium iodide− cells was suppressed only after 250 nM Pc 4/PDT. In contrast, DES knockdown led to enhanced appearance of annexin V+/propidium iodide− cells after 500 nM Pc 4/PDT. Furthermore, DES knockdown resulted in moderate reduction in the appearance of annexin V+/propidium iodide+ cells after both PDT doses. These findings suggest that DES knockdown has a dual, dose-dependent effect on early apoptosis, by making the cells either more resistant or more sensitive to PDT. DES knockdown conferred moderate resistance to late PDT-induced apoptosis. Taken together, these findings support the notion that DES is involved in controlling apoptotic response to PDT.
DES knockdown attenuated PDT-induced cell death. To assess the effect of DES knockdown on cell viability at 24 h post-PDT, the trypan blue dye exclusion assay was used. Approximately 80% of trypan blue-positive cells were detected after treatment with both PDT doses (Figure 4C). Their number was only moderately, but significantly, reduced following DES knockdown.
Discussion
The present study shows that by knocking down DES, levels of dihydroceramides are substantially elevated without any significant changes in ceramides at-rest. Despite the reduction in DES, there are still significant increases in ceramides following PDT. Specifically, at 500 nM Pc 4/PDT levels of global ceramides are higher in siDES cells than in their control counterparts. This increase correlates with enhanced early-apoptosis. However, the cells remain resistant to mitochondrial depolarization, DEVDase activation and late apoptosis. This is likely due to alteration in dihydroceramide/ceramide balance after DES knockdown. Besides increases in global ceramides, the levels of C20- and C24-dihydroceramide are greater in siDES cells. PDT-induced increases in individual dihydroceramides in siDES cells counteract pro-apoptotic effects of ceramide. Our data support the idea that DES affects the dihydroceramide/ceramide balance, and consequently, apoptotic responsiveness to PDT. Similarly, DES-dependent shift in dihydroceramide/ceramide balance has been proposed to control cell growth and death in hypoxia/reoxygenation (22).
The following scenario might be proposed as to how the dihydroceramide/ceramide shift regulates PDT-induced apoptosis: pro-apoptotic ceramide forms channels in the outer mitochondrial membrane and, with activated Bax, synergizes to induce mitochondrial depolarization (23, 24). Elevated dihydroceramides prevent ceramide channel formation (4) to counteract pro-apoptotic effects of ceramide. Since Bax is required for mitochondrial apoptotic pathway after PDT (25), we propose that PDT-induced enhanced levels of C20- and C24-dihydroceramide in siDES cells lead to inhibition of ceramide channel formation to hinder mitochondrial depolarization, with subsequent inhibition of DEVDase activation. Apparently, early apoptosis-related phosphatidylserine translocation to the outer leaflet of the plasma membrane is less impacted by dihydroceramide and more responsive to elevated ceramide levels.
PDT-induced enhanced increases in global ceramide in siDES cells are likely due to incomplete DES knockdown, allowing for de novo ceramide to be formed. The activation of the salvage pathway can be eliminated based on the following: our current findings show that PDT-induced increases in sphingosine are not different between the two cell types, and therefore, are not DES knockdown-dependent; our previous studies showed that acid sphingomyelinase (26) and ceramidase (unpublished observations) are inhibited by PDT.
Oxidative stress has been shown to inhibit DES without affecting DES protein levels (27). In contrast, our current study shows degradation of DES post-treatment with 500 nM Pc 4/PDT in siControl cells. PDT-induced destruction of DES did not further increase accumulation of global dihydroceramides. The loss of DES is likely due to PDT-induced oxidative stress, as our previous studies have shown (9).
Our novel findings have the following implications: (i) dihydroceramide acts as a modifying factor, reducing pro-apoptotic effects of ceramide; (ii) cells adapt to DES knockdown to become more sensitive to ceramide and early apoptosis; (iii) DES is a potential molecular target for regulating apoptotic resistance to PDT.
Acknowledgements
This work was supported by: U.S. Public Health Service Grants from the National Institutes of Health R01 CA77475 (DS), and P20-RR17677 (JMK); grants from the Rally Foundation for Childhood Cancer Research, Hyundai Hope on Wheels, Monica Kreber Golf Tournament, and Chase after a Cure Foundation (JMK); the Veterans Administration Merit Awards from RR&D and BLRD programs (TIG). The MS-related work was performed by the Lipidomics Shared Resource (Medical University of South Carolina), supported by NCI grants: IPO1CA097132 and P30 CA 138313 and NIH/NCRR SC COBRE Grant P20 RR017677. Laboratory space for the Lipidomics Shared Resource was supported by the NIH, grant C06 RR018823 from the Extramural Research Facilities Program of the National Center for Research Resources.
- Received November 15, 2012.
- Revision received November 29, 2012.
- Accepted November 30, 2012.
- Copyright© 2013 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved